KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Current Liabilities (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Total Current Liabilities data on record, last reported at $16.4 billion in Q1 2025.

  • For Q1 2025, Total Current Liabilities rose 5.26% year-over-year to $16.4 billion; the TTM value through Mar 2025 reached $16.4 billion, up 5.26%, while the annual FY2025 figure was $16.5 billion, 2.59% up from the prior year.
  • Total Current Liabilities reached $16.4 billion in Q1 2025 per TAK's latest filing, up from $15.6 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.8 billion in Q1 2023 and bottomed at $15.6 billion in Q1 2024.
  • Average Total Current Liabilities over 5 years is $17.2 billion, with a median of $16.8 billion recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: rose 10.22% in 2022, then decreased 16.81% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $16.8 billion in 2021, then rose by 10.22% to $18.5 billion in 2022, then rose by 1.62% to $18.8 billion in 2023, then fell by 16.81% to $15.6 billion in 2024, then rose by 5.26% to $16.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $16.4 billion in Q1 2025, $15.6 billion in Q1 2024, and $18.8 billion in Q1 2023.